title: The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease.
abstract: This double-blind, randomized parallel group study investigated the effect of 6 months beta-adrenoceptor antagonist therapy with either metoprolol (beta 1-selective without intrinsic sympathomimetic activity [ISA]) or epanolol (beta 1-selective with ISA) on markers of endogenous fibrinolysis in 20 patients with chronic stable angina receiving concurrent treatment with nifedipine. Neither drug had an effect on tissue-type plasminogen activator or plasminogen activator inhibitor type 1 (PAI-1). A significant correlation between fasting insulin and PAI-1 has previously been described and was confirmed in this study. The group treated with metoprolol showed a significant rise in fasting insulin after 6 months with no change in PAI-1. This suggests that the previously described link between these two may not be causal.
authors.affiliation: Cardiovascular Research Unit, University of Edinburgh, UK.
authors.forename: R A
authors.initials: RA
authors.lastname: Wright
authors.forename: A M
authors.initials: AM
authors.lastname: Perrie
authors.forename: F
authors.initials: F
authors.lastname: Stenhouse
authors.forename: K G
authors.initials: KG
authors.lastname: Alberti
authors.forename: R A
authors.initials: RA
authors.lastname: Riemersma
authors.forename: I R
authors.initials: IR
authors.lastname: MacGregor
authors.forename: N A
authors.initials: NA
authors.lastname: Boon
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D044482:Benzeneacetamides; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008790:Metoprolol / Q000009:adverse effects / Q000627:therapeutic use*; D009543:Nifedipine / Q000627:therapeutic use; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D010959:Tissue Plasminogen Activator / Q000097:blood*
chemical_list: D000319:Adrenergic beta-Antagonists; D044482:Benzeneacetamides; D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D017395:Plasminogen Activator Inhibitor 1; D011412:Propanolamines; C038616:epanolol; D010959:Tissue Plasminogen Activator; D008790:Metoprolol; D009543:Nifedipine